Canary App for Alzheimer's Disease

Overseen By Susan Dara, MPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Hackensack Meridian Health

Disqualifiers: Parkinson's, Huntington's, Cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

Research Team

Sakshi Jain, MD

Principal Investigator

Hackensack Meridian Health

Eligibility Criteria

This trial is for individuals who have been diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD). The study aims to include a diverse group of participants to ensure the application can be used widely.

Inclusion Criteria

I am willing and able to give my consent for treatment.

Subjects are free of any medical condition(s) that might audibly affect voice characteristics

I am 50 years old or older.

Exclusion Criteria

Persons with speech characteristics that would interfere with voice recording or voice analysis

I am under 50 years old.

Failure to provide informed consent

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Assessment

Participants' voice characteristics are analyzed using the CANARY application to diagnose MCI and Alzheimer's disease

Upon enrollment

Follow-up

Participants are monitored for accuracy of the application diagnosis compared to clinical diagnosis

4 weeks

Treatment Details

Interventions

• The Canary Application

Trial Overview The study is testing 'The Canary Application,' which uses voice analysis to diagnose MCI and AD. It will compare the app's diagnostic results with those from clinicians to check its accuracy.

Participant Groups

Group I: Mild Cognitive Impairment (MCI) Experimental Treatment 1 Intervention

Group II: Alzheimer's Disease Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Hackensack Meridian Health

Lead Sponsor

Trials

141

Recruited

42,900+

Canary Speech Inc.

Collaborator